Journals Library

An error occurred retrieving publication content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

Six days of daily low-dose prednisolone during an upper respiratory tract infection does not reduce associated relapse of steroid sensitive nephrotic syndrome in UK children.

{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Martin T Christian 1,*,, Nicholas JA Webb 2,, Rebecca L Woolley 3, Nafsika Afentou 4, Samir Mehta 3, Emma Frew 4, Elizabeth A Brettell 3, Adam R Khan 3, David V Milford 5, Detlef Bockenhauer 6, Moin A Saleem 7, Angela S Hall 8, Ania Koziell 9, Heather Maxwell 10, Shivaram Hegde 11, Eric R Finlay 12, Rodney D Gilbert 13, Caroline Jones 14, Karl McKeever 15, Wendy Cook 16, Natalie Ives 3

1 Department of Paediatric Nephrology, Nottingham Children’s Hospital, Nottingham, UK
2 Department of Paediatric Nephrology, University of Manchester, Academic Health Science Centre, Royal Manchester Children’s Hospital, Manchester, UK
3 Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
4 Health Economics Unit, University of Birmingham, Birmingham, UK
5 Department of Paediatric Nephrology, Birmingham Children’s Hospital, Birmingham, UK
6 Department of Renal Medicine, University College London, Department of Paediatric Nephrology, Great Ormond Street Hospital for Children, London, UK
7 School of Clinical Sciences, University of Bristol, Department of Paediatric Nephrology, Bristol Royal Hospital for Children, Bristol, UK
8 Leicester Children’s Hospital, Leicester, UK
9 Child Health Clinical Academic Group, King’s College London, Department of Paediatric Nephrology, Evelina London Children’s Hospital, London, UK
10 Department of Paediatric Nephrology, Royal Hospital for Sick Children, Glasgow, UK
11 Department of Paediatric Nephrology, University Hospital of Wales, Cardiff, UK
12 Department of Paediatric Nephrology, Leeds Children’s Hospital, Leeds, UK
13 Department of Paediatric Nephrology, Southampton Children’s Hospital, Southampton, UK
14 Department of Paediatric Nephrology, Alder Hey Children’s Hospital, Liverpool, UK
15 Department of Paediatric Nephrology, Royal Hospital for Sick Children, Belfast, UK
16 Nephrotic Syndrome Trust (NeST), Taunton, UK
* Corresponding author Email: martin.christian@nuh.nhs.uk

Joint first authors

Joint first authors

Declared competing interests of authors: Martin T Christian is a member of the International Pediatric Nephrology Association Clinical Practice Guideline Group for Steroid Sensitive Nephrotic Syndrome (2020–present). Nicholas JA Webb reports personal fees from Novartis Pharma AG (Basel, Switzerland) outside the submitted work. Nafsika Afentou has received a grant from the National Institute for Health Research (NIHR) for research unrelated to this report (NIHR300440). Emma Frew has received grants from NIHR (nine in the 36 months prior to publication: NIHR300773, 03/164/51, 17/92/39, 14/185/13, 15/184/14, RP-PG-0618-20008, NIHR203012, RP-DG-1215-10002 and NIHR CDF 2015 08 013), UK Research and Innovation (London, UK) (BB/V004832/1) and Zhejiang Yongning Pharmaceutical Co., Ltd (Taizhou, The People’s Republic of China) for research unrelated to this report. Elizabeth A Brettell reports grants from NIHR during the conduct of the study. Other than the grants received for the PREDNOS (PREDnisolone in NephrOtic Syndrome) studies (reference 08/53/31), other NIHR grants received include grants for the ECUSTEC (ECUlizumab in Shiga-Toxin producing Escherichia Coli Haemolytic Uraemic Syndrome) trial (reference 14/48/43) and the GHD (Growth Hormone Deficiency) Reversal Study (reference NIHR127468). Caroline Jones sits on the Paediatric Medicines Expert Advisory Group for the Medicines and Healthcare products Regulatory Agency (January 2017–present).

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}

https://doi.org/{{metadata.DOI}}

Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Crossmark status check

Report Content

The full text of this issue is available as a PDF document from the Toolkit section on this page.

The full text of this issue is available as a PDF document from the Toolkit section on this page.

If you would like to receive a notification when this project publishes in the NIHR Journals Library, please submit your email address below.

Responses to this report

No responses have been published.

 

If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors.  Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

By submitting your response, you are stating that you agree to the terms & conditions

An error has occurred in processing the XML document